Lung AI vs Analytic for Hemodynamic Instability (AHI)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI Verdict

These tools are adjacent rather than direct competitors, as they address different aspects of patient care using distinct AI modalities. Lung AI provides AI-powered real-time diagnostic imaging for cardiac and lung conditions via a handheld ultrasound device. In contrast, Analytic for Hemodynamic Instability (AHI) offers continuous, predictive monitoring of hemodynamic instability using physiological waveform analysis from existing in-hospital systems.

Choose Lung AI if…

Choose Lung AI if your priority is immediate, on-site visual assessment and diagnosis of cardiac and lung conditions using a portable ultrasound device. This tool is ideal for point-of-care scenarios in emergency medicine, critical care, or pulmonology where rapid imaging and AI-assisted interpretation are needed to guide real-time clinical decisions and facilitate training.

View Lung AI →

Choose Analytic for Hemodynamic Instability (AHI) if…

Choose Analytic for Hemodynamic Instability (AHI) if you require continuous, proactive monitoring of hospitalized patients to predict hemodynamic instability hours before traditional vital signs indicate a problem. This software is best suited for critical care settings where early warning of patient deterioration is crucial for timely intervention and reducing the burden of constant manual surveillance.

View Analytic for Hemodynamic Instability (AHI) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Lung AI Analytic for Hemodynamic Instability (AHI)
Pricing Contact for pricing Contact vendor
Deployment On-device (integrated with Exo Iris handheld ultrasound device) Software as a Medical Device (SaMD) integrated into in-hospital monitoring platforms; accessible via any browser-enabled device.
BAA Available Yes AI-estimated Unknown
FDA Status 1 AI-estimated 1 AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool A emphasizes simplifying complex ultrasound imaging with features like 'Guided image capture' and 'SweepAI' for real-time image quality feedback, alongside 'Exo U' for integrated education and training, making advanced diagnostics accessible to a wider range of users. Its design aims to be as easy to use as a smartphone, which significantly enhances usability for a hands-on diagnostic tool.

Clinical Value

Analytic for Hemodynamic Instability (AHI)

Both tools are FDA-cleared and offer significant clinical benefits. However, Tool B provides a critical predictive capability, offering an average of over 26 hours of advanced warning for hemodynamic instability, which can enable proactive, life-saving interventions and significantly improve patient outcomes beyond traditional monitoring. Tool A enhances real-time diagnostic accuracy for lung and cardiac conditions, but Tool B's predictive nature for a life-threatening event offers a more transformative clinical impact.

Pricing & Value

Lung AI

Tool A offers some transparency by stating a starting price for its device and a mandatory annual subscription for its integrated software, explicitly aiming for 'affordable' medical imaging. Tool B's pricing remains undisclosed, making a direct comparison of value difficult without more information. While Tool B's value proposition is strong in terms of preventing adverse events, Tool A's partial pricing disclosure gives it a slight edge in transparency.

Enterprise Readiness

Analytic for Hemodynamic Instability (AHI)

Tool B, as a Software as a Medical Device (SaMD), integrates directly with existing in-hospital monitoring platforms and is accessible via any browser-enabled device, simplifying deployment and scalability within a hospital's current IT infrastructure. While Tool A is HIPAA compliant and integrates with EHRs, its on-device deployment requires managing physical hardware, which can be a larger undertaking for enterprise-wide adoption.

Innovation

Analytic for Hemodynamic Instability (AHI)

Both are highly innovative. Tool A innovates by miniaturizing AI-powered ultrasound diagnostics into a handheld, offline device with real-time guidance, making advanced imaging widely accessible. However, Tool B's ability to *predict* hemodynamic instability hours in advance using existing ECG data represents a more profound innovation, shifting patient care from reactive to proactive and enabling earlier, potentially life-saving interventions.

Support & Docs

Lung AI

Tool A explicitly highlights 'Exo U (AI-powered POCUS education and training)' as a key feature, demonstrating a commitment to user enablement and ongoing learning. Additionally, Exo provides a dedicated support center with multiple contact methods, user manuals, and release notes. Tool B does not provide specific details on support or documentation in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Lung AI Analytic for Hemodynamic Instability (AHI)
Name Lung AI Analytic for Hemodynamic Instability (AHI)
Company Exo Fifth Eye
Tagline Handheld AI Ultrasound for Smarter Cardiac and Lung Scanning. Predicting hemodynamic instability earlier than vital signs for proactive patient care.
Primary AI Application AI for imaging and therapeutic applications, specifically AI-powered detection of pleural effusion, consolidation/atelectasis, and automated AI-based indicators for cardiac conditions. AI-driven clinical decision support software that continuously monitors adult in-hospital patients for signs of hemodynamic instability, providing early warnings.
Core Technology/Input High-performance, handheld ultrasound platform; On-device AI processing. Real-time clinical analytics based on physiologic waveforms; Uses continuous ECG lead II data for analysis.
Specialties Supported Cardiology, Emergency Medicine, Pulmonology Cardiology, Critical Care, Emergency Medicine

Videos

Demos, reviews, and walkthroughs featuring Lung AI and Analytic for Hemodynamic Instability (AHI).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Lung AI, being an on-device AI integrated with a handheld ultrasound device, provides real-time feedback and operates without an internet connection, suggesting that image data would likely need to be exported or manually transferred to the EHR. In contrast, Analytic for Hemodynamic Instability (AHI) is a Software as a Medical Device (SaMD) designed to integrate with existing in-hospital monitoring platforms, such as Sickbay and VitalConnect, allowing for continuous data flow and accessibility via any browser-enabled device.
Lung AI offers AI-powered detection of pleural effusion and consolidation/atelectasis, along with automated AI-based indicators for cardiac conditions. AHI continuously monitors adult in-hospital patients using continuous ECG lead II data to predict hemodynamic instability, providing early warnings up to 26 hours ahead of traditional vital signs.
Lung AI aims for a lower learning curve with its 'easy-to-use' design, 'guided image capture for optimal scans,' and dedicated 'Exo U (AI-powered POCUS education and training)' program. AHI features 'easy-to-interpret visual indicators (red, yellow, green)' to simplify understanding of patient status, suggesting a straightforward interpretation process for clinicians.
Lung AI offers real-time feedback and on-device AI processing for immediate diagnostic support, enabling quick, critical decisions that can improve patient outcomes. AHI provides early warnings of hemodynamic instability hours ahead of traditional vital signs, facilitating proactive patient care and potentially reducing nurse surveillance burden and streamlining workflow.
Lung AI, being a handheld device with on-device AI, may offer simpler multi-site deployment as individual units with integrated training through Exo U. AHI, as a SaMD, requires integration with existing in-hospital monitoring platforms, meaning multi-site rollout would depend on compatibility with diverse IT infrastructures and monitoring systems across different locations.
AI Tool Finder
AI-powered search. Results may not be comprehensive.